Eli Lilly Completes Centessa Pharma Acquisition, Entering Orexin-Based Sleep Medicine

The Quick Take

• Eli Lilly (LLY) completed its acquisition of Centessa Pharmaceuticals, adding orexin receptor 2 agonist assets targeting sleep disorders including narcolepsy to its pipeline
• Centessa's orexin program addresses a commercially validated mechanism following approvals by Jazz Pharmaceuticals and Axsome Therapeutics in the sleep-wake disorder market
• The deal reinforces Lilly's strategy of acquiring clinical-stage assets that can reach blockbuster scale using its global commercial and patient-access infrastructure

Eli Lilly closed its acquisition of Centessa Pharmaceuticals, a clinical-stage biotech focused on orexin receptor 2 agonist development for sleep-wake disorders including narcolepsy. The deal completion gives LLY immediate ownership of Centessa's lead orexin program, which targets the neurological pathways governing wakefulness and sleep transitions. Orexin-based medicines represent one of the fastest-growing areas in sleep medicine following regulatory approvals for mechanistically similar drugs by Jazz Pharmaceuticals (Lumryz) and Axsome Therapeutics (Sunosi), validating the pathway commercially. Lilly's entry into CNS sleep positions the company to compete in a multi-billion-dollar therapeutic area alongside its dominant GLP-1 obesity and diabetes franchise.

Centessa's pipeline centers on orexin receptor 2 (OX2R) agonism, a mechanism validated by approved drugs that restore natural wakefulness signaling disrupted in patients with narcolepsy type 1 and type 2. The clinical-stage nature of the acquired asset means Lilly absorbs development risk alongside the commercial upside, but the validated mechanism substantially reduces regulatory uncertainty compared to first-in-class programs. For LLY shareholders, the transaction adds a near-term pipeline catalyst as Centessa's lead compound advances toward pivotal trials, while diversifying the growth narrative beyond tirzepatide and GLP-1 drugs that currently dominate investor attention and drive the majority of Lilly's revenue forecast.

Eli Lilly's willingness to acquire Centessa reflects a broader capital allocation philosophy: deploy GLP-1 cash flows to fund pipeline diversification in high-value therapeutic categories with durable competitive moats. Sleep medicine complements Lilly's CNS research heritage and orexin franchise would reduce concentration risk in a portfolio dominated by tirzepatide's commercial ramp trajectory. The acquisition also keeps Lilly competitive with Pfizer, AstraZeneca, and other large pharma companies that have been actively targeting clinical-stage biotech assets in underserved disease areas. Until a pivotal data readout or regulatory filing milestone, Centessa's contribution to Lilly's earnings per share will remain modest but strategically significant for pipeline credibility.

Synthesized from 1 source.